Gulf Countries Oncology Market - Forecast(2022 - 2027)

Report Code: HCR 1266 Report Format: PDF + Excel

Gulf Countries Oncology Market Overview

Gulf Countries Oncology Market size is estimated to reach $5.1 billion by 2027, growing at a CAGR of 11.2% during the forecast period 2022-2027. The gulf countries like the United Arab Emirates, Bahrain, Saudi Arabia, Oman, Qatar, and Kuwait, matured breast cancer, colorectal cancer, leukemia, thyroid cancer, and non-Hodgkin lymphomas are the most typical cancers prevailing among younger communities in comparison with other countries. The increasing predominance of cancer in the Gulf countries has been largely attributed to tobacco smoking in 2018. Typical treatment techniques for cancer include chemotherapy, immunotherapy, and radiation therapy. With the onset of biomarkers, there is a considerable boost in targeted, small molecule, and biologic therapies. Chemotherapy persists in being the backbone of cancer treatment and is available to nearly all patients in the Gulf countries. The unsupportive changes in lifestyle and the surging tobacco smoking is set to drive the Gulf Countries Oncology Market resulting in a greater count of cancer cases. The minimized physical activity and heightening intake of unhealthy food are set to propel the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027. This represents the Gulf Countries Oncology Industry Outlook.

Report Coverage

The report: Gulf Countries Oncology Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Gulf Countries Oncology Market.

By Therapeutic Type: Chemotherapy, Immunotherapy, Targeted Therapy, Stem Cell Transplant, Others.
By Therapeutic Application Area: Blood Cancer, Lung Cancer, Breast Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Gastrointestinal Cancer, Others.
By End User: Hospitals, Ambulatory Surgery Centers (ASCs), Clinics.
By Country: Bahrain, Kuwait, Oman, Qatar, Kingdom of Saudi Arabia, United Arab Emirates, Others.

Key Takeaways

  • By country, the Kingdom of Saudi Arabia (KSA) (Gulf Countries Oncology Market) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the soaring high count of cancer patients requiring chemotherapy in the Kingdom of Saudi Arabia region.
  • Gulf Countries Oncology Market growth is being driven by the increasing population of the elderly and the proliferating knowledge regarding the ailment, diagnosis, and recording of cancer cases requiring chemotherapy. However, the lack of advancement in cancer care in comparison with the developed economies is one of the major factors hampering the growth of the Gulf Countries Oncology Market. 
  • Gulf Countries Oncology Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Gulf Countries Oncology Market report. 

Gulf Countries Oncology Market Share, By Therapeutic Application Area, 2021(%):

Gulf Countries Oncology Market Share
For More Details on This Report - Request for Sample

Gulf Countries Oncology Market Segment Analysis – By Therapeutic Type:

The Gulf Countries Oncology Market based on therapeutic type can be further segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Stem Cell Transplant, and Others. The Targeted Therapy Segment held the largest market share in 2021. This growth is owing to the increased application of targeted therapy in the treatment of cancer in conjunction with chemotherapy. The heightening utilization of biomarker levels by healthcare professionals to determine ailment hazards and actualize an anti-cancer plan in terms of analysis, prediction, and selection of targeted therapy are further propelling the growth of the targeted therapy segment.

Furthermore, the Chemotherapy segment is estimated to grow with the fastest CAGR of 12.1% during the forecast period 2022-2027 owing to chemotherapy being the foundation of cancer treatment and is available to nearly all patients.

Gulf Countries Oncology Market Segment Analysis – By Therapeutic Application Area:

The Gulf Countries Oncology Market based on therapeutic application area can be further segmented into Blood Cancer, Lung Cancer, Breast Cancer, Liver Cancer, Skin Cancer, Prostate Cancer, Gastrointestinal Cancer, and Others. The Breast Cancer Segment held the largest market share in 2021. This growth is owing to the high incidence of breast cancer among the younger communities in the Gulf countries when compared to other countries of the world. The reduced physical activity increased awareness campaigns, and an upsurge in tobacco smoking is further propelling the growth of this segment.

Furthermore, the Colorectal Cancer segment is estimated to grow with the fastest CAGR of 12.3% during the forecast period 2022-2027 owing to the increased tobacco smoking and developments of errors in the DNA of healthy cells. The intake of unhealthy food is further propelling the growth of the Colorectal Cancer segment.

Gulf Countries Oncology Market Segment Analysis – By Country:

The Gulf Countries Oncology Market based on the country can be further segmented into Bahrain, Kuwait, Oman, Qatar, Kingdom of Saudi Arabia, United Arab Emirates, and Others. Kingdom of Saudi Arabia (Gulf Countries Oncology Market) held the largest share of the overall market in 2021. The growth of this region is owing to the increasing predominance of cancer in the region. The changes in lifestyle brought in by accelerated modernization and urbanization resulting in greater per capita intake of meat and processed food in conjunction with soaring tobacco smoking are propelling the growth of the Gulf Countries Oncology Market in the Kingdom of Saudi Arabia region.

Furthermore, the Qatar region is estimated to be the region with the fastest CAGR of 12.5% over the forecast period 2022-2027. This growth is owing to factors like surging initiatives to enhance cancer awareness and enhanced screening of patients in the region. The increased tobacco smoking is fuelling the progress of the Gulf Countries Oncology Market in the Qatar region.

Gulf Countries Oncology Market Drivers

Increased Initiatives To Enhance Awareness Of Cancer Are Projected To Drive The Growth Of Gulf Countries Oncology Market:

The predominance of cancer in the Gulf countries has been greatly ascribed to tobacco smoking. There have been numerous initiatives in the gulf countries to enhance the awareness of cancer. In October 2021, Procter & Gamble (P&G) associated with Zulekha Hospital in the UAE and Choithrams for the Pink, It Now campaigns as part of Breast Cancer Awareness month. This initiative aims to raise awareness of the ailment, advance screening, and early testing, and organize funds for research into its cause, prevention, diagnosis, treatment, and cure. On purchases of Dh70 of P&G products like Pampers, Tide, Ariel, and Herbal Essences at Choithrams, purchasers will acquire a free breast cancer consultation and mammogram. Similarly, Qatar Cancer Society (QCS), in collaboration with Qatar Cyclists Centre, coordinated the 'Pink Ride' event with the target of spreading awareness of breast cancer, the techniques of prevention, and early discovery. These kinds of initiatives are fuelling the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027.

Novel Launches And Inclination Towards Targeted Therapies Are Expected To Boost The Demand Of Gulf Countries Oncology:

With the arrival of biomarkers, there is a considerable boost in targeted, small molecule, and biologic therapies. Chemotherapy persists in being the backbone of cancer treatment and is readily available to nearly all patients. There is a robust oncology pipeline in development with numerous late-stage next-generation Biotherapeutics and many immuno-oncology therapies presently in development across all stages. Gulf countries have become considerably accessible with inspiring accomplishments in terms of cancer drugs authorizations since 2015. The greatest count of authorizations was observed in Saudi Arabia and Lebanon. UAE comes first among the Gulf countries in the acceptance of novel checkpoint inhibitors. These kinds of advancements are driving the growth of the Gulf Countries Oncology Market during the forecast period 2022-2027.

Gulf Countries Oncology Market Challenges

Challenges In R&D And Impact Of COVID-19 Pandemic Are Hampering The Growth Of The Gulf Countries Oncology Market:

Oncology persists as the most demanding area for research and development, encountering considerable hazards of failure and lengthy duration. Obstacles to acceptance of novel drugs persist, delaying patient gain from treatment advances. As treatment alternatives become more including alternatives like immunotherapy, the effect on spending levels has evolved into a focal area across most parts of the globe, which is a trend that is anticipated to continue over the consequent five years with unceasing development. The gulf countries trail behind the developed world in terms of advancement in cancer care. Access to novel therapy in the Gulf countries is hard despite the rising predominance of cancer and proactive actions taken by the governments. The COVID pandemic has not only constrained accessible resources but has also influenced the early discovery of cancer as screening actions have taken a back-seat. These issues are hampering the growth of the Gulf Countries Oncology Market.

Gulf Countries Oncology Industry Outlook

Novel launches, mergers, and acquisitions switch towards targeted therapies, immune-oncology therapies, and next-generation biotherapeutics, robust oncology pipeline in development and greatest count of approvals are key strategies adopted by players in the Market. Gulf Countries Oncology top 10 companies include:

  1. NUPCO, Kingdom of Saudi Arabia (KSA)
  2. AbbVie Inc, UAE
  3. Amgen, Gulf Countries (Saudi Arabia, UAE, Kuwait, Bahrain, Oman, and Qatar)
  4. Astellas MEA
  5. Roche, UAE
  6. Johnson & Johnson, Middle East
  7. Elekta Gulf, Kingdom of Saudi Arabia (KSA)
  8. Varian Medical Systems Inc., Middle East
  9. Accuray Incorporated, Middle East
  10. Life Pharma, Middle East

Acquisitions/Product Launches:

  • In October 2021, Astellas Pharma commenced utilizing sugarcane-derived polyethylene as 50% of its raw material for building pharmaceutical blister packs. As per the firm, the move depicts “the world’s first use” of biomass plastic for drug blister packs. Astellas will begin utilizing the biomass-based plastic blister pack for its “Irribow Tablet 5µg” tablets on the Japanese market, which target diarrhea-predominant irritable bowel syndrome.
  • In October 2021, Roche declared that it has introduced the AVENIO Tumor Tissue CGP Kit. The Kit augments the present CGP portfolio provided by Roche and Foundation Medicine and permits laboratories to extend their oncology research in-house. Eventually, a forthcoming version of the kit can result in added resources for clinicians to utilize in the diagnosis and treatment of cancer.
  • In April 2021, Allergan Aesthetics, an AbbVie firm declared the introduction of SkinMedica® Neck Correct Cream, the earliest product from the professional-grade skin care line formulated to attend to the particular biology of the skin on the neck and décolleté area. SkinMedica® Neck Correct Cream was planned to avert the early signs and treat the visible countenance of moderate to serious neck aging. It is clinically proven to stabilize and stiffen the look of creepy skin, avert and minimize the look of baggy, level deep lines and wrinkles and improve skin tone evenness.

Related Reports:

Oncology Market – Forecast (2021 - 2026)

Report Code: HCR 1226

Oncology Information System Market – Forecast (2021 - 2026)

Report Code: HCR 0436 

For more Lifesciences and Healthcare Market reports, please click here

1. Gulf Countries Oncology Market Overview
    1.1 Definitions and Scope
2. Gulf Countries Oncology Market - Executive Summary
3. Gulf Countries Oncology Market– Market Landscape
    3.1 Company Benchmarking- Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis 
4. Gulf Countries Oncology Market– Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Gulf Countries Oncology Market– Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Gulf Countries Oncology Market- Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Gulf Countries Oncology Market– By Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Gulf Countries Oncology Market - By Therapeutic Type (Market Size –$Million/$Billion) 
    8.1 Chemotherapy
    8.2 Immunotherapy
    8.3 Targeted Therapy
    8.4 Stem Cell Transplant
    8.5 Others
9. Gulf Countries Oncology Market - By Therapeutic Application Area (Market Size –$Million/$Billion) 
    9.1 Blood Cancer
    9.2 Lung Cancer
    9.3 Breast Cancer
    9.4 Liver Cancer
    9.5 Skin Cancer
    9.6 Prostate Cancer
    9.7 Gastrointestinal Cancer
    9.8 Others
10. Gulf Countries Oncology Market - By End User (Market Size –$Million/$Billion) 
    10.1 Hospitals
    10.2 Ambulatory Surgery Centers (ASCs)
    10.3 Clinics
11. Gulf Countries Oncology Market- By Country (Market Size -$Million/Billion)
    11.1 Bahrain
    11.2 Kuwait
    11.3 Oman
    11.4 Qatar
    11.5 Kingdom of Saudi Arabia
    11.6 United Arab Emirates
    11.7 Others
12. Gulf Countries Oncology Market- Market Entropy
    12.1 New product launches
    12.2 M&A's, collaborations, JVs, and partnerships
13. Gulf Countries Oncology Market– Industry Competition Landscape (Premium)
    13.1 Market Share Analysis
    13.1.2 Market Share by Region – Key Companies
    13.1.3 Market Share by Country – Key Companies
    13.2 Competition Matrix
    13.3 Best Practices for Companies
14. Gulf Countries Oncology Market– Key Company List by Country Premium (Premium)
15. Gulf Countries Oncology Market- Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
"*Financials would be provided on a best-efforts basis for private companies"
List of Tables:

Table1: Gulf Countries Oncology Market Overview 2019-2024
Table2: Gulf Countries Oncology Market Leader Analysis 2018-2019 (US$)
Table3: Gulf Countries Oncology Market Product Analysis 2018-2019 (US$)
Table4: Gulf Countries Oncology Market End User Analysis 2018-2019 (US$)
Table5: Gulf Countries Oncology Market Patent Analysis 2013-2018* (US$)
Table6: Gulf Countries Oncology Market Financial Analysis 2018-2019 (US$)
Table7: Gulf Countries Oncology Market Driver Analysis 2018-2019 (US$)
Table8: Gulf Countries Oncology Market Challenges Analysis 2018-2019 (US$)
Table9: Gulf Countries Oncology Market Constraint Analysis 2018-2019 (US$)
Table10: Gulf Countries Oncology Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table11: Gulf Countries Oncology Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table12: Gulf Countries Oncology Market Threat of Substitutes Analysis 2018-2019 (US$)
Table13: Gulf Countries Oncology Market Threat of New Entrants Analysis 2018-2019 (US$)
Table14: Gulf Countries Oncology Market Degree of Competition Analysis 2018-2019 (US$)
Table15: Gulf Countries Oncology Market Value Chain Analysis 2018-2019 (US$)
Table16: Gulf Countries Oncology Market Pricing Analysis 2019-2024 (US$)
Table17: Gulf Countries Oncology Market Opportunities Analysis 2019-2024 (US$)
Table18: Gulf Countries Oncology Market Product Life Cycle Analysis 2019-2024 (US$)
Table19: Gulf Countries Oncology Market Supplier Analysis 2018-2019 (US$)
Table20: Gulf Countries Oncology Market Distributor Analysis 2018-2019 (US$)
Table21: Gulf Countries Oncology Market Trend Analysis 2018-2019 (US$)
Table22: Gulf Countries Oncology Market Size 2018 (US$)
Table23: Gulf Countries Oncology Market Forecast Analysis 2019-2024 (US$)
Table24: Gulf Countries Oncology Market Sales Forecast Analysis 2019-2024 (Units)
Table25: Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table26: Gulf Countries Oncology Market By Therapeutic Type, Revenue & Volume, By Chemotherapy, 2019-2024 ($)
Table27: Gulf Countries Oncology Market By Therapeutic Type, Revenue & Volume, By Immunotherapy, 2019-2024 ($)
Table28: Gulf Countries Oncology Market By Therapeutic Type, Revenue & Volume, By Targeted Therapy, 2019-2024 ($)
Table29: Gulf Countries Oncology Market By Therapeutic Type, Revenue & Volume, By Stem Cell Transplant, 2019-2024 ($)
Table30: Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table31: Gulf Countries Oncology Market By Therapeutic Application Area, Revenue & Volume, By Blood Cancer, 2019-2024 ($)
Table32: Gulf Countries Oncology Market By Therapeutic Application Area, Revenue & Volume, By Lung Cancer, 2019-2024 ($)
Table33: Gulf Countries Oncology Market By Therapeutic Application Area, Revenue & Volume, By Breast Cancer, 2019-2024 ($)
Table34: Gulf Countries Oncology Market By Therapeutic Application Area, Revenue & Volume, By Liver Cancer, 2019-2024 ($)
Table35: Gulf Countries Oncology Market By Therapeutic Application Area, Revenue & Volume, By Skin Cancer, 2019-2024 ($)
Table36: Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table37: Gulf Countries Oncology Market By End User, Revenue & Volume, By Hospitals, 2019-2024 ($)
Table38: Gulf Countries Oncology Market By End User, Revenue & Volume, By Ambulatory Surgery Centers (ASCs), 2019-2024 ($)
Table39: Gulf Countries Oncology Market By End User, Revenue & Volume, By Clinics, 2019-2024 ($)
Table40: North America Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table41: North America Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table42: North America Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table43: South america Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table44: South america Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table45: South america Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table46: Europe Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table47: Europe Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table48: Europe Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table49: APAC Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table50: APAC Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table51: APAC Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table52: Middle East & Africa Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table53: Middle East & Africa Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table54: Middle East & Africa Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table55: Russia Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table56: Russia Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table57: Russia Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table58: Israel Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Type, 2019-2024 ($)
Table59: Israel Gulf Countries Oncology Market, Revenue & Volume, By Therapeutic Application Area, 2019-2024 ($)
Table60: Israel Gulf Countries Oncology Market, Revenue & Volume, By End User, 2019-2024 ($)
Table61: Top Companies 2018 (US$) Gulf Countries Oncology Market, Revenue & Volume
Table62: Product Launch 2018-2019 Gulf Countries Oncology Market, Revenue & Volume
Table63: Mergers & Acquistions 2018-2019 Gulf Countries Oncology Market, Revenue & Volume


List of Figures:

Figure 1: Overview of Gulf Countries Oncology Market 2019-2024
Figure 2: Market Share Analysis for Gulf Countries Oncology Market 2018 (US$)
Figure 3: Product Comparison in Gulf Countries Oncology Market 2018-2019 (US$)
Figure 4: End User Profile for Gulf Countries Oncology Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Gulf Countries Oncology Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Gulf Countries Oncology Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Gulf Countries Oncology Market 2018-2019
Figure 8: Ecosystem Analysis in Gulf Countries Oncology Market 2018
Figure 9: Average Selling Price in Gulf Countries Oncology Market 2019-2024
Figure 10: Top Opportunites in Gulf Countries Oncology Market 2018-2019
Figure 11: Market Life Cycle Analysis in Gulf Countries Oncology Market
Figure 12: GlobalBy Therapeutic Type Gulf Countries Oncology Market Revenue, 2019-2024 ($)
Figure 13: GlobalBy Therapeutic Application Area Gulf Countries Oncology Market Revenue, 2019-2024 ($)
Figure 14: GlobalBy End User Gulf Countries Oncology Market Revenue, 2019-2024 ($)
Figure 15: Global Gulf Countries Oncology Market - By Geography
Figure 16: Global Gulf Countries Oncology Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 17: Global Gulf Countries Oncology Market CAGR, By Geography, 2019-2024 (%)
Figure 18: North America Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 19: US Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 20: US GDP and Population, 2018-2019 ($)
Figure 21: US GDP – Composition of 2018, By Sector of Origin
Figure 22: US Export and Import Value & Volume, 2018-2019 ($)
Figure 23: Canada Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 24: Canada GDP and Population, 2018-2019 ($)
Figure 25: Canada GDP – Composition of 2018, By Sector of Origin
Figure 26: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 27: Mexico Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 28: Mexico GDP and Population, 2018-2019 ($)
Figure 29: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 30: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 31: South America Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 32: Brazil Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 33: Brazil GDP and Population, 2018-2019 ($)
Figure 34: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 35: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 36: Venezuela Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 37: Venezuela GDP and Population, 2018-2019 ($)
Figure 38: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 39: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 40: Argentina Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 41: Argentina GDP and Population, 2018-2019 ($)
Figure 42: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 43: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 44: Ecuador Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 45: Ecuador GDP and Population, 2018-2019 ($)
Figure 46: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 47: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 48: Peru Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 49: Peru GDP and Population, 2018-2019 ($)
Figure 50: Peru GDP – Composition of 2018, By Sector of Origin
Figure 51: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 52: Colombia Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 53: Colombia GDP and Population, 2018-2019 ($)
Figure 54: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 55: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 56: Costa Rica Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 57: Costa Rica GDP and Population, 2018-2019 ($)
Figure 58: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 59: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 60: Europe Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 61: U.K Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 62: U.K GDP and Population, 2018-2019 ($)
Figure 63: U.K GDP – Composition of 2018, By Sector of Origin
Figure 64: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 65: Germany Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 66: Germany GDP and Population, 2018-2019 ($)
Figure 67: Germany GDP – Composition of 2018, By Sector of Origin
Figure 68: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 69: Italy Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 70: Italy GDP and Population, 2018-2019 ($)
Figure 71: Italy GDP – Composition of 2018, By Sector of Origin
Figure 72: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 73: France Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 74: France GDP and Population, 2018-2019 ($)
Figure 75: France GDP – Composition of 2018, By Sector of Origin
Figure 76: France Export and Import Value & Volume, 2018-2019 ($)
Figure 77: Netherlands Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 78: Netherlands GDP and Population, 2018-2019 ($)
Figure 79: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 80: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 81: Belgium Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 82: Belgium GDP and Population, 2018-2019 ($)
Figure 83: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 84: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 85: Spain Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 86: Spain GDP and Population, 2018-2019 ($)
Figure 87: Spain GDP – Composition of 2018, By Sector of Origin
Figure 88: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 89: Denmark Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 90: Denmark GDP and Population, 2018-2019 ($)
Figure 91: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 92: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 93: APAC Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 94: China Gulf Countries Oncology Market Value & Volume, 2019-2024
Figure 95: China GDP and Population, 2018-2019 ($)
Figure 96: China GDP – Composition of 2018, By Sector of Origin
Figure 97: China Export and Import Value & Volume, 2018-2019 ($) Gulf Countries Oncology Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 98: Australia Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 99: Australia GDP and Population, 2018-2019 ($)
Figure 100: Australia GDP – Composition of 2018, By Sector of Origin
Figure 101: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 102: South Korea Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 103: South Korea GDP and Population, 2018-2019 ($)
Figure 104: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 105: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 106: India Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 107: India GDP and Population, 2018-2019 ($)
Figure 108: India GDP – Composition of 2018, By Sector of Origin
Figure 109: India Export and Import Value & Volume, 2018-2019 ($)
Figure 110: Taiwan Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 111: Taiwan GDP and Population, 2018-2019 ($)
Figure 112: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 113: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 114: Malaysia Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 115: Malaysia GDP and Population, 2018-2019 ($)
Figure 116: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 117: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 118: Hong Kong Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 119: Hong Kong GDP and Population, 2018-2019 ($)
Figure 120: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 121: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 122: Middle East & Africa Gulf Countries Oncology Market Middle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 123: Russia Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 124: Russia GDP and Population, 2018-2019 ($)
Figure 125: Russia GDP – Composition of 2018, By Sector of Origin
Figure 126: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 127: Israel Gulf Countries Oncology Market Value & Volume, 2019-2024 ($)
Figure 128: Israel GDP and Population, 2018-2019 ($)
Figure 129: Israel GDP – Composition of 2018, By Sector of Origin
Figure 130: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 131: Entropy Share, By Strategies, 2018-2019* (%) Gulf Countries Oncology Market
Figure 132: Developments, 2018-2019* Gulf Countries Oncology Market
Figure 133: Company 1 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 134: Company 1 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 135: Company 1 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 136: Company 2 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 137: Company 2 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 138: Company 2 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 139: Company 3 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 140: Company 3 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 141: Company 3 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 142: Company 4 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 143: Company 4 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 144: Company 4 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 145: Company 5 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 146: Company 5 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 147: Company 5 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 148: Company 6 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 149: Company 6 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 150: Company 6 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 151: Company 7 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 152: Company 7 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 153: Company 7 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 154: Company 8 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 155: Company 8 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 156: Company 8 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 157: Company 9 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 158: Company 9 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 159: Company 9 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 160: Company 10 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 161: Company 10 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 162: Company 10 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 163: Company 11 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 164: Company 11 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 165: Company 11 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 166: Company 12 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 167: Company 12 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 168: Company 12 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 169: Company 13 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 170: Company 13 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 171: Company 13 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 172: Company 14 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 173: Company 14 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 174: Company 14 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)
Figure 175: Company 15 Gulf Countries Oncology Market Net Revenue, By Years, 2018-2019* ($)
Figure 176: Company 15 Gulf Countries Oncology Market Net Revenue Share, By Business segments, 2018 (%)
Figure 177: Company 15 Gulf Countries Oncology Market Net Sales Share, By Geography, 2018 (%)